Loading cancer entity…
Loading cancer entity…
Clinical trials
341 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03862885 | Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST | approved for marketing | — | — | Blueprint Medicines CorporationINDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT04148092 | Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST | approved for marketing | — | — | Deciphera Pharmaceuticals, LLCINDUSTRY | 0 | May 29, 2020 |
| clinicaltrials |
Data updated 22 days agoSource updated Jul 27, 2020source: clinicaltrials